Critical Path Institute (C-Path) and the Center for Health + Technology (CHeT) at University of Rochester as we speak introduced the discharge of two seminal publications about digital well being applied sciences for Parkinson’s. These applied sciences, reminiscent of smartphones and wearable sensors, supply a chance for goal, frequent and distant evaluation of individuals with Parkinson’s.

With 10 million individuals dwelling with Parkinson’s worldwide, collaboration and information sharing are essential for driving innovation in drug growth for the fastest-growing degenerative neurological situation.

Research leaders at CHeT have joined forces with organizations and regulators via C-Path’s Critical Path for Parkinson’s (CPP) Consortium, a precompetitive public-private partnership. CPP goals to speed up the regulatory endorsement of digital instruments in Parkinson’s medical trials via its Digital Drug Development Tools (3DT) initiative.

In June 2023, the Journal of Parkinson’s Disease printed two open entry manuscripts, representing companion papers from this partnership that element steps in conducting interviews of individuals with Parkinson’s who participated in a medical analysis examine utilizing smartphones. The manuscripts report on related signs in early Parkinson’s and assess the relevance of digital measures from a smartphone utility and smartwatch from the affected person perspective.

The examine was led by Jamie Adams, M.D., Associate Professor of Neurology and Associate Director of CheT on the University of Rochester and Jennifer Mammen, Ph.D., Assistant Professor on the University of Rhode Island, with help from CPP.

This undertaking pioneers a brand new path to effectively advance instruments aligned with the affected person voice by partaking with regulatory companies early and sometimes. C-Path stays dedicated to studying what issues most to individuals dwelling with Parkinson’s.”

Diane Stephenson, Ph.D., CPP Executive Director

Access the total manuscripts right here:

“These manuscripts describe a novel methodology that will help inform the use of digital health technologies in clinical trials for Parkinson’s disease and support more objective and patient-centered measures. The goal is to enable efficient, data-driven, and patient-centric utilization of digital health technologies to speed therapeutic development,” stated Adams. “Sharing the results with the study participants and witnessing how this information helped them in new ways has been most rewarding.”

John Crawford, a CPP advisor, Parkinson’s advocate, and manuscript coauthor states, “Digital health technologies have the potential to significantly impact Parkinson’s management and have already revolutionized clinical trial conduct. Their advancement expedites trials, enhances intelligence, reduces costs, and ultimately accelerates the delivery of new therapies and technologies to patients.”

The new publications coincide with CPP’s participation within the World Parkinson’s Congress happening in Barcelona, Spain July 4-7, 2023. CPP will current two posters, Recommendations for Parkinson’s Clinical Trials utilizing Digital Health Technologies and Worldwide Collaborative Framework for Optimizing New Parkinson’s Treatment Trials with Patient Centric Outcome Measures, on the convention coauthored by individuals dwelling with Parkinson’s highlighting the significance of worldwide collaborations.